Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis. The study involved dosing hamsters over a 2-week period with concentrations 5-8 times higher than planned for the upcoming pilot efficacy study in patients.
The results demonstrated high drug tolerance in all test subjects, with no adverse reactions or irritation at the buccal application site. Notably, necroscopic cross examination revealed no tissue changes. This successful completion marks a significant milestone for Orocidin, paving the way for the upcoming pivotal eight-week toxicity study.
Orocidin A/S, una filiale di Nordicus Partners (OTCQB: NORD), ha completato con successo il suo primo studio di tossicità per QR-01, un nuovo trattamento per la parodontite aggressiva. Lo studio ha coinvolto la somministrazione di dosi a criceti per un periodo di 2 settimane con concentrazioni 5-8 volte superiori a quelle previste per il prossimo studio pilota di efficacia nei pazienti.
I risultati hanno dimostrato un'alta tolleranza al farmaco in tutti i soggetti testati, senza reazioni avverse o irritazione nel sito di applicazione buccale. È interessante notare che l'esame necroscopico non ha rivelato cambiamenti tissutali. Questo completamento riuscito segna un traguardo significativo per Orocidin, aprendo la strada per il prossimo studio di tossicità cruciale della durata di otto settimane.
Orocidin A/S, una subsidiaria de Nordicus Partners (OTCQB: NORD), ha completado con éxito su primer estudio de toxicidad para QR-01, un nuevo tratamiento para la periodontitis agresiva. El estudio involucró la administración de dosis a hámsters durante un período de 2 semanas con concentraciones de 5 a 8 veces más altas de lo planeado para el próximo estudio piloto de eficacia en pacientes.
Los resultados demostraron una alta tolerancia al fármaco en todos los sujetos de prueba, sin reacciones adversas ni irritación en el sitio de aplicación bucal. Cabe destacar que el examen necroscópico no reveló cambios en los tejidos. Esta finalización exitosa marca un hito significativo para Orocidin, allanando el camino para el próximo estudio de toxicidad crucial de ocho semanas.
Orocidin A/S는 Nordicus Partners (OTCQB: NORD)의 자회사로, 공격적인 치주염 치료를 위한 새로운 약물 QR-01의 첫 번째 독성 연구를 성공적으로 완료했습니다. 이 연구는 2주 동안 햄스터에게 예정된 환자 파일럿 효능 연구보다 5-8배 높은 농도로 투여하는 방식으로 진행되었습니다.
결과는 모든 시험 대상에서 약물의 높은 내약성을 보여주었으며, 구강 적용 부위에서 부작용이나 자극이 없었습니다. 특히, 부검 결과 조직 변화가 없음을 확인했습니다. 이 성공적인 완료는 Orocidin에게 중요한 이정표가 되며, 향후 8주 독성 연구를 위한 길을 열어주었습니다.
Orocidin A/S, une filiale de Nordicus Partners (OTCQB: NORD), a réussi à terminer sa première étude de toxicité pour QR-01, un nouveau traitement pour la parodontite agressive. L'étude a impliqué l'administration de doses à des hamsters pendant une période de 2 semaines avec des concentrations 5 à 8 fois plus élevées que prévu pour la prochaine étude pilote d'efficacité chez les patients.
Les résultats ont montré une grande tolérance au médicament chez tous les sujets testés, sans réactions indésirables ni irritation au site d'application buccale. Il est à noter que l'examen nécroscopique n'a révélé aucun changement tissulaire. Cette réussite marque une étape importante pour Orocidin, ouvrant la voie à la prochaine étude de toxicité cruciale de huit semaines.
Orocidin A/S, eine Tochtergesellschaft von Nordicus Partners (OTCQB: NORD), hat erfolgreich ihre erste Toxizitätsstudie für QR-01, eine neuartige Behandlung von aggressiver Parodontitis, abgeschlossen. Die Studie umfasste die Verabreichung von Dosen an Hamster über einen Zeitraum von 2 Wochen mit Konzentrationen, die 5-8 mal höher waren als geplant für die bevorstehende Pilotstudie zur Wirksamkeit bei Patienten.
Die Ergebnisse zeigten eine hohe Arzneimittelverträglichkeit bei allen Testpersonen, ohne unerwünschte Reaktionen oder Reizungen an der buccalen Applikationsstelle. Besonders hervorzuheben ist, dass die nekroskopische Untersuchung keine Gewebeveränderungen ergab. Dieser erfolgreiche Abschluss markiert einen bedeutenden Meilenstein für Orocidin und ebnet den Weg für die bevorstehende entscheidende achtwöchige Toxizitätsstudie.
- Successful completion of initial toxicity study for QR-01
- No adverse reactions or safety concerns observed at 5-8x planned dosage
- Clear path forward to eight-week pivotal toxicity study
- None.
BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has successively completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.
In the study, Orocidin dosed hamsters over a 2-week period with a concentration 5-8 times higher than the planned dose for the upcoming pilot efficacy study in patients.
“We are pleased to report that all animals exhibited high tolerance to the drug, with no adverse reactions and irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues.” said Allan Wehnert, CEO & Founder of Orocidin.
The successful completion of this study marks an important milestone for Orocidin, providing the foundation for the upcoming pivotal eight-week toxicity study.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What were the results of Orocidin's QR-01 toxicity study for NORD stock?
What is the next step for Orocidin's QR-01 development program (NORD)?
How does the QR-01 toxicity study impact NORD's development timeline?
What safety profile did Orocidin's QR-01 demonstrate in the preclinical study?
